Group 1 - The company has revised its articles of association to clarify the role and responsibilities of the legal representative, stating that the general manager (president) is the legal representative and that the company will appoint a new legal representative within thirty days of resignation [1] - The company has added provisions regarding the legal consequences of civil activities conducted by the legal representative on behalf of the company, stating that the company will bear the legal consequences of such activities [1] - The company has established that shareholders holding more than 3% of shares for over 180 days can request to inspect the company's accounting books and vouchers, with the company having the right to refuse if it believes the request is made for improper purposes [4][5] Group 2 - The company has set a limit on financial assistance provided to individuals for acquiring shares of the company or its parent company, stating that the total amount of such assistance cannot exceed 10% of the issued share capital [2] - The company has clarified that resolutions made by the shareholders' meeting or board of directors that violate laws or regulations can be declared invalid by shareholders [6] - The company has specified that if a resolution is made without proper procedures or if the required number of votes is not met, the resolution can be challenged in court within 60 days [6][7] Group 3 - The company has established that the board of directors must ensure compliance with laws and regulations when making decisions, and that any disputes regarding the validity of resolutions should be promptly brought to court [6][7] - The company has outlined the responsibilities of the audit committee, including the review of financial reports and the hiring of external auditors [27][28] - The company has introduced provisions to protect the rights of minority shareholders, ensuring that independent directors can supervise potential conflicts of interest [32][29]

Core Viewpoint - The announcement details the upcoming election of the 11th Board of Directors for Jianmin Pharmaceutical Group Co., Ltd., following the expiration of the 10th Board's term, highlighting the nomination of candidates and the process for their election [1][3]. Group 1: Board Election Process - The 11th Board of Directors will consist of nine members, with eight candidates nominated for election by the shareholders' meeting, including both non-independent and independent directors [3][4]. - The candidates for the 11th Board include Pei Rong, Wang Siyang, Yuan Pingdong, Wang Jun, and Xu Liang as non-independent directors, and Guo Yunpei, Yang Zhi, and Xin Jinguo as independent directors [1][2]. Group 2: Candidate Qualifications - The candidates have been deemed qualified to serve as directors, with no disqualifying conditions as per relevant laws and regulations, and no recent administrative penalties from the China Securities Regulatory Commission [2]. - The independent director candidates possess the necessary educational backgrounds and work experiences to fulfill their responsibilities, having obtained the required qualifications recognized by the China Securities Regulatory Commission [2]. Group 3: Future Arrangements - Following the approval of the revised Articles of Association, a new employee director will be elected through a democratic process, alongside the directors elected by the shareholders [3]. - The term for the newly elected Board members will be three years, starting from the date of the shareholders' meeting approval [3]. Group 4: Acknowledgments - The company expresses gratitude to outgoing Chairman He Qin and independent director Li Shuqiu for their contributions to the company's development during their tenure [4].

Core Viewpoint - The company plans to continue its asset pool business with Zhejiang Commercial Bank, with a credit limit of 400 million yuan and a term of 12 months from the approval of the shareholders' meeting [1][2][3] Summary by Sections Asset Pool Business Overview - The asset pool business allows the company and its subsidiaries to manage and utilize their assets collectively, providing a comprehensive service platform for asset management and financing [1][2] - The financing limit for the asset pool is set at 400 million yuan, which accounts for 16.43% of the company's latest audited net assets of 2,435.31 million yuan [2][3] Guarantee Methods and Parties Involved - The company will provide maximum pledge guarantees, utilizing various forms of collateral such as certificates of deposit, bills, and margin deposits [2][3] - The maximum financing limit for the subsidiary, Guangdong Fuga Pharmaceutical Co., Ltd., is capped at 56 million yuan, with the company assuming joint liability for guarantees [3][4] Financial Status - As of March 31, 2025, the company's total assets were 427,768.32 million yuan, with net assets of 254,548.31 million yuan and a debt-to-asset ratio of 40.15% [5] - The subsidiary, Guangdong Fuga Pharmaceutical Co., Ltd., reported total assets of 58,102.82 million yuan and net assets of 4,952.81 million yuan as of March 31, 2025 [6] Agreements and Contracts - The company intends to sign a cooperation agreement with Zhejiang Commercial Bank for the asset pool business, which includes provisions for collateral rights and various financing methods [7][8] - A guarantee agreement will be established with Guangzhou Hongshan Investment Co., Ltd., which will pledge its entire equity in Fuga Pharmaceutical as collateral for financing within the asset pool limit [8][9] Impact and Risk Control - The asset pool business is expected to enhance the efficiency of the company's bill assets, reduce financial costs, and maximize shareholder equity [9][10] - The company will implement measures to manage liquidity risks associated with the asset pool, including tracking the collection of pledged bills and ensuring timely repayments [10][11]

Group 1 - The core point of the announcement is the proposed amendments to the company's articles of association and related governance systems to align with new regulations and improve corporate governance [1][2][3] - The main content of the amendments includes the removal of the supervisory board and its responsibilities, which will be transferred to the audit committee of the board of directors [1][2] - The amendments also introduce new sections regarding the responsibilities and obligations of controlling shareholders and actual controllers, as well as clarifying the roles of independent directors and board committees [2][3] Group 2 - The company plans to enhance its internal audit system and improve internal control capabilities as part of the governance reforms [2] - The amendments will require shareholder meetings to be referred to as "shareholders' meetings" and will specify certain timelines and definitions [2][3] - The proposed amendments and related governance documents will be disclosed on the Shanghai Stock Exchange website simultaneously with the announcement [3]

证券代码：600976 证券简称：健民集团 公告编号：2025-023 健民药业集团股份有限公司 关于修改《公司章程》及相关制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《中华人民共和国公司法（2023 年修订）》及中国证监会发布的《关 于新〈公司法〉配套制度规则实施相关过渡期安排》《上市公司章程指引（2025 年修订）》《上市公司治理准则（2025 年修订）》《上市公司股东会规则（2025 年修订）》《上海证券交易所上市公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》等规定，健民药业集团股份有限公司（以下简称"公司"）拟结 合公司实际情况修订《健民药业集团股份有限公司章程》（简称《公司章程》）， 并配套修订相关公司治理制度。 新增独立董事专节。进一步明确独立董事的任职条件、职权等事项。 一、《公司章程》修订的主要内容 1、删除监事会及监事（含职工监事）相关规定 根据《上市公司章程指引》的相关规定，为进一步规范公司治理结构，拟删 除监事会、监事等相关内容，监事会相关职责拟由董事会审计 ...

证券代码：600976 证券简称：健民集团 公告编号：2025-024 健民药业集团股份有限公司 关于健民集团关于开展资产池业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司拟在浙商银行股份有限公司继续开展资产池业务，授信额度 40,000 万元，授信期限自股东大会批准之日起 12 个月。 担保情况：最高额质押担保，出质物均为公司及下属子公司合法持有的 票据等资产。 健民药业集团广东福高药业有限公司股东广州红珊投资有限公司自愿以 其持有的该公司全部股权及其派生利益为健民集团基于健民药业集团广东福高 药业有限公司资产池授信额度内开展的融资业务所承担的质押担保提供反担保。 根据健民药业集团股份有限公司（以下简称：公司或健民集团）2024年9月 30日召开的2024年第一次临时股东大会决议，公司及控股子公司在4亿元的额度 范围内开展资产池业务，业务期限不超过1年，该项业务即将到期。为提高公司 票据资产的使用效率，减少资金占用，降低财务费用，公司拟继续在浙商银行股 份有限公司武汉分行（以下简称：浙商 ...

健民药业集团股份有限公司 制度文件 二○二五年七月十四日 1 健民药业集团股份有限公司 股东会议事规则 (2025 修订稿，本规则尚需股东会批准) 第一章 总则 第一条 为规范公司行为，维护健民药业集团股份有限公司（以下简称公司）及公司股东 的合法权益，规范股东会议事程序，保证公司股东会能够公平、公正、高效、有序地行使职权， 根据《公司法》《证券法》《上市公司股东会规则》及《健民药业集团股份有限公司章程》的规 定，特制订本议事规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、法规、公司章程及本规则的相关规定召开股东会，保证 公司股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当勤勉尽责，确 保股东会正常召开和依法行使职权。 第四条 股东会在《公司法》和《公司章程》规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次，应当于上一会 计年度结束后的六个月内举行。临时股东会不定期召开，出现《公司法》第一百一十三条规定 的应当召开临时股东会的情形时，临时股东会应当在两个月内召开。 公司在上述期 ...

证券代码：600976 证券简称：健民集团 公告编号：2025-022 健民药业集团股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 鉴于健民药业集团股份有限公司（以下简称"公司"）第十届董事会任期即 将届满，根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证 券交易所股票上市规则》等法律、法规、规范性文件及《健民药业集团股份有限 公司章程》（以下简称"《公司章程》"）的相关规定，公司开展董事会换届选 举相关工作，具体如下： 一、第十一届董事会成员提名情况 取监管谈话，除此之外本次提名的候选人没有被中国证券监督管理委员会的行政 处罚或证券交易所惩戒情况。本次提名的独立董事候选人的教育背景、工作经历 均能够胜任独立董事的职责要求，符合《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》《上市公司独立董事管理办法》中有关独立董事任职资格 及独立性的相关要求，并均已取得中国证监会认可的独立董事任职资格，在上海 证券交易所备案审核无异议。 二、换届工作后续安排 根据《公 ...

| 情形收购本公司股份的，应当经股东大会 | 份的，应当经股东大会决议；公司因本章程第二十 | | --- | --- | | 决议；公司因本章程第二十五条第一款第 | 五条第一款第（三）项、第（五）项、第（六）项 | | （三）项、第（五）项、第（六）项规定 | 规定的情形收购本公司股份的，可以依照本章程的 | | 的情形收购本公司股份的，经三分之二以 | 规定或者股东会的授权，经三分之二以上董事出席 | | 上董事出席的董事会会议决议。 | 的董事会会议决议。 | | 其余内容不做修订。 | 其余内容不做修订。 | | 第三十四条 股东提出查阅前条所述 | 第三十五条 股东要求查阅、复制公司有关材料 | | 有关信息或者索取资料的，应当向公司提 | 的，应当遵循《公司法》《证券法》等法律法规及规 | | 供证明其持有公司股份的种类以及持股 | 范性文件的规定向公司提出书面申请，说明目的， | | 数量的书面文件，公司经核实股东身份后 | 并向公司出示证明其持有公司股份的种类及数量的 | | 按照股东的要求予以提供。 | 书面文件，经公司核实股东身份等信息后方可依法 | | | 提供。 | | | 连续一百 ...

健民药业集团股份有限公司独立董事提名人声明 提名人健民药业集团股份有限公司董事会，现提名郭云沛/杨智 为健民药业集团股份有限公司第十一届董事会独立董事候选人，并已 充分了解被提名人职业专长、教育背景、工作经历、兼任职务等情况。 被提名人已书面同意出任健民药业集团股份有限公司第十一届董事 会独立董事候选人（参见该独立董事候选人声明）。提名人认为，被 提名人具备独立董事任职资格，与健民药业集团股份有限公司之间不 存在任何影响其独立性的关系，具体声明如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、规章及其他规范性文件，具有五年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要 求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事规则》的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用） ...